Home/Biosimilar Atlas/Companies/Formycon

Formycon

Biosimilar developer, Germany. 2 development products across 2 molecules: aflibercept, ustekinumab.

First approval in the Atlas: Jun 2024, Ahzantive, aflibercept (FDA)
FDAproducts approved2
EMAproducts approved2
MHRAproducts approved2
PMDAproducts approved0
HCproducts approved1
CDSCOproducts approved0
EDEproducts registered0
Connections
2molecules2products4 of 7markets0candidates in trials6companies on the same molecules

Portfolio by market

MoleculeProductFDAEMAMHRAPMDAHCCDSCOEDEMarkets
AfliberceptAhzantive / Baiama FYB203Jun 2024Jan 2025MHRA····3/7
UstekinumabOtulfi / Fymskina FYB202Sep 2024Sep 2024MHRA·Dec 2024··4/7

Month shown is the first approval or registration of that product in that market.

Companies on the same molecules

Developers whose portfolios overlap most with Formycon, by number of shared molecules. Overlap is the clearest sign of who competes with whom for the same tenders and licensing partners.

AlvotechTwo shared molecules: aflibercept, ustekinumab5 molecules in its portfolioAmgenTwo shared molecules: aflibercept, ustekinumab8 molecules in its portfolioBiocon BiologicsTwo shared molecules: aflibercept, ustekinumab9 molecules in its portfolioCelltrionTwo shared molecules: aflibercept, ustekinumab10 molecules in its portfolioFuji PharmaTwo shared molecules: aflibercept, ustekinumab5 molecules in its portfolioSamsung BioepisTwo shared molecules: aflibercept, ustekinumab10 molecules in its portfolio

Chronology

Compare Formycon with other developers on the comparison page.

Considering a partner, a licence or a new market for a biosimilar portfolio? EvySaif's regulatory strategy and value dossier work covers the regulatory and market-access side of that decision.

Planning your biosimilar strategy?

EvySaif can help assess your regulatory pathway, clinical evidence requirements and market-entry strategy across India, UAE and other target markets.

Talk to a biosimilar regulatory consultant
Data current to September 2026.